cpx-351 plus venetoclax in patients with newly-diagnosed high-risk aml
Published 3 months ago • 150 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
3:03
cpx-351 vs. hma plus venetoclax in the treatment of patients with aml
-
2:21
cpx-351 for high-risk aml
-
2:05
safety and efficacy of cpx-351 in newly diagnosed aml patients under the age of 60
-
1:55
cardiotoxicity of cpx-351 vs 7 3 chemotherapy in patients with untreated high-risk aml
-
0:52
a real-world study of the optimal duration of cpx-351 treatment in patients with aml
-
1:12
cpx-351 with venetoclax in r/r aml: results of a phase ib study
-
5:04
evaluating cpx-351 against 7 3 in older newly diagnosed aml
-
3:31
risk stratified analysis of cpx-351 versus 7 3 in older adults with aml
-
3:35
safety and efficacy of venetoclax-based regimens for aml
-
3:02
cbc-lifotronic 3-part hematology analyzer ac310
-
2:49
results of a phase i trial investigating cynk-001, a placental nk-cell product, in patients with aml
-
5:03
combining venetoclax with cpx-351 for aml
-
1:19
predicting the outcomes of patients with aml treated with cpx-351 based on eln risk stratification
-
3:11
intensive chemotherapy: why the modern approach of cpx-351 is important for cure in aml
-
1:12
cpx-351 and gemtuzumab ozogamicin in r/r aml and mds
-
4:16
cpx-351: liposomal daunorubicin/cytarabine for aml
-
2:01
analyzing the cost-effectiveness of cpx-351 in patients with aml
-
3:20
safety run-in of a phase ii trial of cpx-351 plus pomalidomide in aml with mds-related changes
-
1:34
v-fast subgroup analysis: cpx-351 plus midostaurin for newly diagnosed flt3-mutated aml
-
1:08
the real-world safety and efficacy of cpx-351 in patients with aml
-
1:42
cpx-351 versus intensive induction chemo in pts with taml or aml with myelodysplasia-related changes
-
2:29
cpx-351 vs 7 3 in older high-risk aml patients